Achillion Pharmaceuticals, Inc.
300 George Street
New Haven,
CT 06511
United States - Map
Phone: 203-624-7000
Fax: 203-624-7003
Web Site: http://www.achillion.com
| Achillion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of treatments for infectious diseases. The company focuses on the development of antivirals for the treatment of chronic hepatitis C and HIV infection; and the development of antibacterials for the treatment of resistant bacterial infections. Its products include ACH-1095, a NS4A antagonist that is in late-stage preclinical studies for the treatment of chronic hepatitis C infections; ACH-1625, a protease inhibitor, which is in the preparation for phase I initiation for the treatment of chronic hepatitis C infections; ACH-702, a preclinical candidate that is in preclinical stage with potency against a spectrum of bacterial pathogens, including methicillin-resistant staphylococcus aureus for drug resistant bacterial infections; and Elvucitabine, which completed phase II studies for the treatment of HIV infection. The company has a collaboration arrangement with Gilead Sciences, Inc. to develop and commercialize compounds for use in treating hepatitis C infection, which inhibit viral replication through a mechanism of action. The company was founded in 1998 and is based in New Haven, Connecticut. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Michael D. Kishbauch , 59
Chief Exec. Officer, Pres |
$
471.00K |
$
0 | Ms. Mary Kay Fenton , 45
Chief Financial Officer, Principal Accounting Officer, VP of Fin. & Admin. and Sec. |
$
247.00K |
$
1.00K | Dr. Milind S. Deshpande Ph.D., 52
Chief Scientific Officer and Exec. VP of Research |
$
339.00K |
$
0 | Dr. Gautam Shah Ph.D., 52
Chief Compliance Officer and Sr. VP |
$
312.00K |
$
0 | Dr. Elizabeth A. Olek D.O., 44
Chief Medical Officer and VP |
$
308.00K |
$
0 |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
2.03% Nasdaq 
Profile
